Status:
COMPLETED
Study of Safety, Efficacy, and Pharmacokinetics of Topical ACD440 in Healthy Volunteers
Lead Sponsor:
AlzeCure Pharma
Conditions:
Pain
Eligibility:
All Genders
18-64 years
Phase:
PHASE1
Brief Summary
Phase 1 b placebo-controlled study in healthy volunteers to study safety, efficacy and pharmacokinetics of Topical ACD440 on normal skin, skin optimized for penetration and skin exposed to ultraviolet...
Detailed Description
This is an exploratory study, no primary or secondary endpoints are being defined.
Eligibility Criteria
Inclusion
- Healthy volunteer
- Fitzpatrick skin type II or III
- Women not childbearing potential or highly effective contraception
Exclusion
- Pregnancy, lactation
- Drug abuse
- Clinically significant illness
- Positive COVID 19 test at screening or COVID 19 infection in the past
Key Trial Info
Start Date :
January 12 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 10 2021
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04704232
Start Date
January 12 2021
End Date
March 10 2021
Last Update
November 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AlzeCure Pharma investigational site
Stockholm, Sweden